Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Standigm

Standigm

Standigm is a drug development AI company founded by Jinhan Kim, Sang Ok Song, and So Jeong Yun.

Standigm is a company that develops an artificial intelligence (AI) platform for drug development. It was established in 2015 by Jinhan Kim, Sang Ok Song, and So Jeong Yun. It has received funding from investors such as Mirae Asset Venture Investment, Kakao Ventures, and LB Investment. The company is headquartered in Seoul, South Korea.

Product and Service
Standigm BEST

Standigm's AI platform, called Standigm BEST, allows pharmaceutical companies to generate novel drug compounds or chemical analogs. Its drug discovery latent space allows its clients to design compounds at the molecular level. It is possible to determine the final compound structure based on the pre-determined novel seed molecule or chemical analog property.

Standigm Insight

Standigm Insight is intended to complement their clients' in-house drug discovery process to predict compound activity in the early phase of development, alongside indication prediction, pathway and therapeutic pattern, and target prioritization in the later phases.

Timeline

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Web

News

Title
Author
Date
Publisher
Description
FinSMEs
July 6, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Yimie Yong
March 8, 2021
DealStreetAsia
Ryde is targeting to raise $148 million in a Catalist listing slated for 2022.

References

Golden logo
By using this site, you agree to our Terms & Conditions.